Meridian Bioscience Stock Price and Value Analysis

Should you buy Meridian Bioscience stock? (NasdaqGS:VIVO). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This stock looks overpriced.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the VIVO Numbers

VIVO Price
(Meridian Bioscience stock price per share)
$33.06
[?] VIVO Fair Price
(based on intrinsic value)
$12.41
[?] VIVO Safety Price (based on a variable margin of safety) $8.07
[?] PE Ratio versus Sector 1% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Diagnostics & Research stocks
[?] Cash Yield 3.10%
[?] Free Cash Flow Jitter 40%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,238,895 shares shorted. With 38,625,692 shares available for purchase and an average trading volume over the past 10 trading days of 882,790, it would take at least 2.536 days for all of the short holders to cover their shorts.

Is Meridian Bioscience Stock on Sale?

We believe that Meridian Bioscience may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Meridian Bioscience looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Should You Buy VIVO Stock?

Does Meridian Bioscience have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.